asco@alo33:170246
|
Background: Combination chemotherapy ith taxane and platinum, ith or ithout anthracycline, has been the standard first-line chemotherapy regime for metastatic endometrial cancer EC and there is no standard second-line. The purpose of this study as to evaluate the efficacy of second-line platinum-based chemotherapy in this setting. Methods: We analyzed retrospectively a cohort of patients treated ith second line chemotherapy for metastatic EC, from Jan2005 to Dec2015, at 2 Brazilian cancer centers. Primary endpoint as the analysis of overall survival beteen patients treated ith platinum rechallenge PR compared to other second-line treatments. Overall survival OS and progression free survival PFS ere calculated from the beginning of second line chemotherapy. Platinum free interval PFI as defined as the time from last platinum infusion in the first line to the beginning of second line chemotherapy. We used Kaplan-Meier method for survival analysis, log-rank test to compare survival curves, Cox regression to multivariable analysis and Chi-square or Fishers exact test ere used to compare proportions among groups. Results: A total of 83 patients ere evaluated. Median age as 66.2 years, most of them ECOG performance status 1-2 78 percent , endometrioid histology 70 percent and grade 2 tumors 44 percent . All patients, but one, received platinum based chemotherapy at first-line. At second-line 44 percent 3682 ere PR and of them 66.6 percent had PFI 6 months. Median follo-up as 27.6m 20.734.5m . Re-exposure carboplatin plus paclitaxel achieved higher overall response rate ORR compared to other regimens 42.9 percent vs 13.3 percent; p = 0.01 . Median OS as 9.7 m 7-12.3m and PFS, 4.1 m 3.4-4.8m . PR as associated ith a higher median PFS, 5.2 2.9-7.5 vs 3.2m 1.7-4.6 for non re-exposed p = 0.004 , and OS, 13.9 9.48-18.25m vs 7.9 m 5.32-10.45m p = 0.005 . PR remain the only factor independently related to OS in multivariate analysis HR 0.5; 0.25-0.98 CI95 percent; p = 0.044 . Conclusions: Re-exposure to platinum based chemotherapy in second-line for metastatic endometrial cancer is associated ith higher response rates, PFS and OS.,J Clin Oncol 34, 2016 suppl; abstr e17108 ,Publication Only Gynecologic Cancer
|